title: [Post-stroke depression: recognition and treatment interventions].
abstract: Depression is the most common neuropsychiatric complication of a stroke (Post Stroke DepressionPSD) and has been shown to impede the recovery and rehabilitation of these patients. Prevalence  rates of PSD vary between 6% and 79%. Direct comparison between studies is limited due to their  different methodology. Etiology of PSD is determined by biological and psychosocial factors.  Symptoms of PSD appear in three areas: affective, somatic and cognitive. Differential diagnosis  includes post-stroke fatigue and pseudo-depressive manifestations of ischemic infarctions (apathy, aprosody, athymhormia, pseudobulbar palsy). Mortality in post-stroke patients is higher than  in non-depressed stroke patients and suicide ideation is observed in 6.6-11.3% of stroke patients.  Selective serotonin reuptake inhibitors (SSRI) are considered as the first choice treatment of PSD.  Other therapeutic approaches include cognitive and functional rehabilitation. PSD is a potentially  treatable condition, yet under-diagnosed, and has a negative effect on functional recovery and survival of stroke patients.
authors.affiliation: Department of Psychiatry, Democritus University of Thrace, Alexandroupolis, Greece. stelios977@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Arseniou
authors.forename: A
authors.initials: A
authors.lastname: Arvaniti
authors.forename: M
authors.initials: M
authors.lastname: Samakouri
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality / Q000523:psychology*; D006801:Humans; D011379:Prognosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000150:complications* / Q000401:mortality / Q000523:psychology*; D059020:Suicidal Ideation
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors